- Home
- GMM vs BTAI Comparison
GMM vs BTAI Comparison
Compare GMM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMM | BTAI |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 49.2M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GMM | BTAI |
|---|---|---|
| Price | $1.13 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 16.3K | ★ 578.0K |
| Earning Date | 08-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | $0.72 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $1.17 |
| 52 Week High | $4.97 | $9.26 |
Technical Indicators
Market Signals| Indicator | GMM | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 44.03 |
| Support Level | $1.28 | $1.82 |
| Resistance Level | $1.41 | $2.30 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.25 | 11.78 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.